|
WO2008005534A2
|
|
Orally dissolving formulations of memantine
|
|
US2007134322A1
|
|
Modified and pulsatile release pharmaceutical formulations of escitalopram
|
|
WO2006138227A1
|
|
Modified and immediate release memantine bead formulation
|
|
WO2007120136A1
|
|
Lercanidipine ph dependent pulsatile release compositions
|
|
WO2007120135A1
|
|
Lercanidipine immediate release composition
|
|
WO2007120134A1
|
|
Lercanidipine modified release compositions
|
|
US2006205822A1
|
|
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
US2006211650A1
|
|
Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
|
|
US2007117826A1
|
|
Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
|
|
US2006165789A1
|
|
Lercanidipine modified release compositions
|
|
US2006134212A1
|
|
Lercanidipine immediate release compositions
|
|
TW200616608A
|
|
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
|
US2006002999A1
|
|
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
|
WO2006009769A1
|
|
Modified release formulation of memantine
|
|
WO2005055996A1
|
|
Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality
|
|
US2005149569A1
|
|
Electronic lab notebook
|
|
CN1870984A
|
|
Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
|
|
KR20060030469A
|
|
Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
|
|
CA2507851A1
|
|
Combination of ibuprofen and oxycodone for acute pain relief
|
|
US5527822A
|
|
Method of treatment of traumatic brain injury
|
